We are studying a new treatment using modified T cells for patients with relapsed or refractory CD19+ lymphoid diseases like leukemia and lymphoma. The goal is to see if this approach can safely reduce cancer and improve patient outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Acute Lymphoblastic Leukemia (ALL) Recurrent is a type of blood cancer that affects the bone marrow and blood, characterized by the rapid production of immature white blood cells. When it recurs, it means the cancer has returned after treatment.
Non-Hodgkin's Lymphoma (NHL) Refractory is a type of cancer that originates in the lymphatic system and does not respond to standard treatments. It can manifest in various forms and may require alternative therapies.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.